XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting - Schedule of Segment Revenue and Operating Income (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Mar. 31, 2022
USD ($)
Mar. 31, 2023
USD ($)
segment
Mar. 31, 2022
USD ($)
Segment Reporting [Abstract]      
Number of operating segments | segment   2  
Segment Reporting Information [Line Items]      
Revenues   $ 666.2 $ 596.2
Adjusted EBITDA   90.1 77.1
Reconciliation of Adjusted EBITDA:      
(Loss) income before income taxes   (0.4) 44.1
Net income attributable to non-controlling interests   (26.1) (30.6)
Interest expense, net   46.8 56.3
Depreciation and amortization   33.7 27.4
Equity-based compensation expense   4.2 3.7
Transaction, integration and acquisition costs   12.8 7.1
Net loss (gain) on disposals, consolidations and deconsolidations   10.5 (0.1)
Litigation settlements and regulatory change impact   8.0 (30.8)
Undesignated derivative activity   0.6 0.0
Adjusted EBITDA   90.1 77.1
Transaction and integration costs   12.5 7.1
Start-up costs   0.3  
(Loss) gain on litigation settlement $ 32.8 (3.0) 32.8
Other litigation costs   0.6 2.0
Additional interest expense for Florida LOP regulation change   4.4  
Surgical Facility Services      
Reconciliation of Adjusted EBITDA:      
Net loss (gain) on disposals, consolidations and deconsolidations   (8.5)  
Operating Segments | Surgical Facility Services      
Segment Reporting Information [Line Items]      
Revenues   649.0 578.8
Adjusted EBITDA   118.8 101.0
Reconciliation of Adjusted EBITDA:      
Adjusted EBITDA   118.8 101.0
Operating Segments | Ancillary Services      
Segment Reporting Information [Line Items]      
Revenues   17.2 17.4
Adjusted EBITDA   (1.4) 0.1
Reconciliation of Adjusted EBITDA:      
Adjusted EBITDA   (1.4) 0.1
All other      
Segment Reporting Information [Line Items]      
Adjusted EBITDA   (27.3) (24.0)
Reconciliation of Adjusted EBITDA:      
Adjusted EBITDA   $ (27.3) $ (24.0)